Updates in the Treatment of Pulmonary Arterial Hypertension

Gain perspectives from experts on various policy issues and therapeutic areas through our Insights series that engages multiple managed care stakeholders in video interviews.

The Future of PAH
October 11, 2016 – 
Charles Burger, MD, outlines 2-drug and 3-drug combination therapy trials going forward, and clinical practicality of targeting bone morphogenetic protein receptors in pulmonary arterial hypertension.
Managed Care's Role in Future Treatment of PAH
August 29, 2016 – 
Derek van Amerongen, MD, MS, describes the changing landscape of pulmonary arterial hypertension from a managed care perspective and the role of managed care companies in improving awareness of trials of novel therapies.
PAH Treatment Driven by Data From Peer-Reviewed Literature
August 29, 2016 – 
Derek van Amerongen, MD, MS, discusses how incorporating data from peer-reviewed literature for pulmonary arterial hypertension leads to optimal patient outcomes.
Hospitalization in PAH
August 29, 2016 – 
Charles Burger, MD, provides insight on the results of three large clinical trials showing reduced hospitalization for patients with pulmonary arterial hypertension.
Optimizing PAH Treatment in Managed Care
August 29, 2016 – 
Derek van Amerongen, MD, MS, outlines decision making in pulmonary arterial hypertension treatment to achieve optimal clinical outcomes for the patient.
PAH: Multidisciplinary Care and Medication Benefits
August 29, 2016 – 
Charles Burger, MD, discusses the role of multidisciplinary care and the clinical benefits of the medications for patients with pulmonary arterial hypertension.
Long-Term Outcomes and Managing PAH Costs
August 22, 2016 – 
Derek van Amerongen, MD, MS, provides insight on how long-term outcomes impact formulary decisions and the total cost of care in patients with pulmonary arterial hypertension.
The Importance of a Patient-Centered Approach in PAH
August 22, 2016 – 
Derek van Amerongen, MD, MS, describes the importance of nursing care and specialty pharmacy services for managing patients with pulmonary arterial hypertension.
Understanding the Newer Options in PAH
August 15, 2016 – 
Charles Burger, MD, describes the mechanism of action of modern oral prostanoids, and discusses how the latest guidelines address the use of combination therapy in pulmonary arterial hypertension.
Prostacyclins in PAH: Selecting Among the Agents
August 15, 2016 – 
Charles Burger, MD, provides insight on some of the clinical and practical considerations when deciding among the oral, inhaled, and infusion prostacyclin therapies in pulmonary arterial hypertension.
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.